Meta-analysis of primary breast tumors demonstrated that HIF-2α expression was higher in HER2-overexpressing samples when compared to Luminal A, Luminal B and basal subtypes, and survival analysis revealed HIF-2α expression was associated with worse prognosis in patients in the HER2-positive group when compared to HER2-negative [76]. This evidence concerns the gene EPAS1 and breast neoplasm.